{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:18:40Z","timestamp":1777951120221,"version":"3.51.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T00:00:00Z","timestamp":1774396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T00:00:00Z","timestamp":1777852800000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006469","name":"Fundo para o Desenvolvimento das Ci\u00eancias e da Tecnologia","doi-asserted-by":"publisher","award":["file no. 005\/2023\/SKL"],"award-info":[{"award-number":["file no. 005\/2023\/SKL"]}],"id":[{"id":"10.13039\/501100006469","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004733","name":"Universidade de Macau","doi-asserted-by":"publisher","award":["MYRG-GRG2023-00087-ICMS"],"award-info":[{"award-number":["MYRG-GRG2023-00087-ICMS"]}],"id":[{"id":"10.13039\/501100004733","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Educ"],"DOI":"10.1186\/s12909-026-09078-x","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T10:49:00Z","timestamp":1774435740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Developing a consensus-based competency framework for hospital pharmacists in the management of advanced therapy medicinal products (ATMPs): a modified delphi study in Macao"],"prefix":"10.1186","volume":"26","author":[{"given":"Junnan","family":"SHI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"HU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolina Oi Lam","family":"UNG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,25]]},"reference":[{"key":"9078_CR1","doi-asserted-by":"publisher","first-page":"108612","DOI":"10.1016\/j.biotechadv.2025.108612","volume":"83","author":"C Frederico","year":"2025","unstructured":"Frederico C, Concei\u00e7\u00e3o A, N\u00f3brega C, Mendon\u00e7a LS. Advanced therapy medicinal products development - from guidelines to medicines in the market. Biotechnol Adv. 2025;83:108612.","journal-title":"Biotechnol Adv"},{"key":"9078_CR2","unstructured":"National Medical Products Administration. Scope, classification and definition of advanced therapy medicinal products (Draft for Comments). 2025. Available at: https:\/\/www.cde.org.cn\/main\/news\/viewInfoCommon\/0d19d9228c90f124053e92cda08331e0. Accessed\u00a0 24\u00a0Aug 2025."},{"key":"9078_CR3","doi-asserted-by":"publisher","first-page":"921","DOI":"10.3389\/fphar.2019.00921","volume":"10","author":"C Iglesias-L\u00f3pez","year":"2019","unstructured":"Iglesias-L\u00f3pez C, Agust\u00ed A, Obach M, Vallano A. Regulatory framework for advanced therapy medicinal products in Europe and United States. Front Pharmacol. 2019;10:921.","journal-title":"Front Pharmacol"},{"issue":"2","key":"9078_CR4","doi-asserted-by":"publisher","first-page":"101485","DOI":"10.1016\/j.omtm.2025.101485","volume":"33","author":"J Shi","year":"2025","unstructured":"Shi J, Yang J, Zheng Y, Wong PHH, Hu H, Ung COL. The clinical quality management system of advanced therapy medicinal products in the hospital setting: a scoping review. Mol Ther Methods Clin Dev. 2025;33(2):101485.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"12","key":"9078_CR5","doi-asserted-by":"publisher","first-page":"780","DOI":"10.14740\/jocmr3964","volume":"12","author":"A Goula","year":"2020","unstructured":"Goula A, Gkioka V, Michalopoulos E, et al. Advanced therapy medicinal products challenges and perspectives in regenerative medicine. J Clin Med Res. 2020;12(12):780\u20136.","journal-title":"J Clin Med Res"},{"issue":"5","key":"9078_CR6","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1016\/j.xphs.2020.08.027","volume":"110","author":"M Sharpe","year":"2021","unstructured":"Sharpe M, Barry J, Kefalas P. Clinical adoption of advanced therapies: challenges and opportunities. J Pharm Sci. 2021;110(5):1877\u201384.","journal-title":"J Pharm Sci"},{"issue":"1","key":"9078_CR7","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12913-024-12026-4","volume":"25","author":"J Shi","year":"2025","unstructured":"Shi J, Chen X, Hu H, Ung COL. The role of hospital pharmacists in supporting the appropriate and safe use of CGT\/ATMPs: a scoping review of current insights. BMC Health Serv Res. 2025;25(1):52.","journal-title":"BMC Health Serv Res"},{"issue":"3","key":"9078_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.sapharm.2019.06.007","volume":"16","author":"N Arakawa","year":"2020","unstructured":"Arakawa N, Yamamura S, Duggan C, Bates I. The development of a foundation-level pharmacy competency framework: an analysis of country-level applicability of the global competency framework. Res Social Adm Pharm. 2020;16(3):396\u2013404.","journal-title":"Res Social Adm Pharm"},{"issue":"3","key":"9078_CR9","doi-asserted-by":"publisher","first-page":"95","DOI":"10.6007\/IJARPED\/v9-i3\/8223","volume":"9","author":"SC Wong","year":"2020","unstructured":"Wong SC. Competency definitions, development and assessment: A brief review. IJARPED. 2020;9(3):95\u2013114.","journal-title":"IJARPED"},{"issue":"1","key":"9078_CR10","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1186\/s12909-024-05428-9","volume":"24","author":"O Janssens","year":"2024","unstructured":"Janssens O, Andreou V, Embo M, et al. The identification of requirements for competency development during work-integrated learning in healthcare education. BMC Med Educ. 2024;24(1):427.","journal-title":"BMC Med Educ"},{"issue":"9","key":"9078_CR11","first-page":"755","volume":"11","author":"MA Arifin","year":"2021","unstructured":"Arifin MA. Competence, competency, and competencies: a misunderstanding in theory and practice for future reference. Int J Acad Res Bus Social Sci. 2021;11(9):755\u201364.","journal-title":"Int J Acad Res Bus Social Sci"},{"issue":"5","key":"9078_CR12","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.sapharm.2018.06.017","volume":"15","author":"TC Koehler","year":"2019","unstructured":"Koehler TC, Bok H, Westerman M, Jaarsma D. Developing a competency framework for pharmacy technicians: perspectives from the field. Res Social Adm Pharm. 2019;15(5):514\u201320.","journal-title":"Res Social Adm Pharm"},{"key":"9078_CR13","unstructured":"International Pharmaceutical Federation. A global competency framework version 1. FIP, The Hague., 2012. Available at: http:\/\/www.fip.org\/files\/fip\/PharmacyEducation\/GbCF_v1.pdf. Accessed 24 Aug 2025."},{"key":"9078_CR14","unstructured":"International Pharmaceutical Federation. Pharmaceutical workforce development goals. international pharmaceutical federation, The Hague., 2016. Available at: http:\/\/www.fip.org\/files\/fip\/PharmacyEducation\/Global_Conference_docs\/WDGs_online_version.pdf. Accessed 24 Aug 2025."},{"key":"9078_CR15","unstructured":"World Health Organization. Transforming and scaling up health professional education and training: policy brief on regulation of health professions education. 2013. Available at: https:\/\/wfme.org\/wp-content\/uploads\/2020\/04\/PolicyBrief_Accreditation_WHO_2013.pdf. Accessed 24 Aug 2025."},{"issue":"4","key":"9078_CR16","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.sapharm.2020.06.023","volume":"17","author":"A Al-Haqan","year":"2021","unstructured":"Al-Haqan A, Smith F, Bader L, Bates I. Competency development for pharmacy: adopting and adapting the global competency framework. Res Social Adm Pharm. 2021;17(4):771\u201385.","journal-title":"Res Social Adm Pharm"},{"issue":"5","key":"9078_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/phar.1923","volume":"37","author":"JJ Saseen","year":"2017","unstructured":"Saseen JJ, Ripley TL, Bondi D, et al. ACCP clinical pharmacist competencies. Pharmacotherapy. 2017;37(5):630\u20136.","journal-title":"Pharmacotherapy"},{"key":"9078_CR18","unstructured":"Association of Faculties of Pharmacy of Canada. Educational outcomes for first professional degree programs in pharmacy in Canada. 2017. Available at: https:\/\/www.afpc.info\/system\/files\/public\/AFPC%20Educational%20Outcomes%202017_User%20Manual%20Section%20E_User%20Guide%20for%20PROFESSIONAL%20ROLE_final%20Jun2018.pdf. Accessed 6 March 2026."},{"issue":"5","key":"9078_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1055\/s-0034-1385158","volume":"35","author":"F Ingravallo","year":"2014","unstructured":"Ingravallo F, Dietrich CF, Gilja OH, Piscaglia F. Guidelines, clinical practice recommendations, position papers and consensus statements: definition, preparation, role and application. Ultraschall Med. 2014;35(5):395\u20139.","journal-title":"Ultraschall Med"},{"key":"9078_CR20","first-page":"29","volume":"13","author":"AG Vulto","year":"2007","unstructured":"Vulto AG, Stoner N, Bal\u00e1sova H, et al. European Association of Hospital Pharmacists (EAHP) guidance on the pharmacy handling of gene medicines. EJHP Pract. 2007;13:29\u201339.","journal-title":"EJHP Pract"},{"issue":"1","key":"9078_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36834\/cmej.77098","volume":"14","author":"B Thoma","year":"2023","unstructured":"Thoma B, Abbott C, Snell L. The future of the CanMEDS physician competency framework. Can Med Educ J. 2023;14(1):1\u20133.","journal-title":"Can Med Educ J"},{"issue":"2","key":"9078_CR22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41409-021-01463-y","volume":"57","author":"E Trias","year":"2022","unstructured":"Trias E, Juan M, Urbano-Ispizua A, Calvo G. The hospital exemption pathway for the approval of advanced therapy medicinal products: an underused opportunity? The case of the CAR-T ARI-0001. Bone Marrow Transpl. 2022;57(2):156\u20139.","journal-title":"Bone Marrow Transpl"},{"issue":"5","key":"9078_CR23","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/j.jcyt.2025.04.026","volume":"27","author":"LC Leon-Moreno","year":"2025","unstructured":"Leon-Moreno LC, Couto S, Caicedo A, et al. The impact of the regulatory landscape on research, public acceptance, and market development of advanced therapies in Latin America. Cytotherapy. 2025;27(5):e16.","journal-title":"Cytotherapy"},{"issue":"746","key":"9078_CR24","doi-asserted-by":"publisher","first-page":"eadn1902","DOI":"10.1126\/scitranslmed.adn1902","volume":"16","author":"KW Doxzen","year":"2024","unstructured":"Doxzen KW, Adair JE, Fonseca Bazzo YM, et al. The translational gap for gene therapies in low- and middle-income countries. Sci Transl Med. 2024;16(746):eadn1902.","journal-title":"Sci Transl Med"},{"key":"9078_CR25","unstructured":"CPC Central Committee and the State Council. Outline development plan for the Guangdong-Hong Kong-Macao Greater Bay Area. 2019. Available at: https:\/\/www.gov.cn\/gongbao\/content\/2019\/content_5370836.htm. Accessed 24 Aug 2025."},{"key":"9078_CR26","unstructured":"Fosun Pharma. The first Yescarta\u00ae CAR-T cell therapy center in Macao established at Kiang Wu Hospital. 2024. Available at: https:\/\/www.fosunpharma.com\/content\/details38_11905.html. Accessed 24 Aug 2025."},{"key":"9078_CR27","unstructured":"IASO Bio. The Macao Drug Administration approved IASO Bio\u2019s CAR-T product Equecabtagene Autoleucel Injection for marketing. 2025. Available at: https:\/\/cn.iasobio.com\/phone\/info.php?id=321. Accessed 24 Aug 2025."},{"key":"9078_CR28","unstructured":"Therapeutics JW. CAR-T product (Relmacabtagene Autoleucel Injection) approved for marketing by the Macao Drug Administration. 2025. Available at: https:\/\/www.jwtherapeutics.com\/cn\/media\/press-release\/20250604. Accessed\u00a0 24\u00a0Aug 2025."},{"issue":"1","key":"9078_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s41073-022-00122-0","volume":"7","author":"WT Gattrell","year":"2022","unstructured":"Gattrell WT, Hungin AP, Price A, et al. ACCORD guideline for reporting consensus-based methods in biomedical research and clinical practice: a study protocol. Res Integr Peer Rev. 2022;7(1):3.","journal-title":"Res Integr Peer Rev"},{"issue":"1","key":"9078_CR30","doi-asserted-by":"publisher","first-page":"e1004326","DOI":"10.1371\/journal.pmed.1004326","volume":"21","author":"WT Gattrell","year":"2024","unstructured":"Gattrell WT, Logullo P, van Zuuren EJ, et al. ACCORD (ACcurate COnsensus Reporting Document): a reporting guideline for consensus methods in biomedicine developed via a modified Delphi. PLoS Med. 2024;21(1):e1004326.","journal-title":"PLoS Med"},{"issue":"5","key":"9078_CR31","doi-asserted-by":"publisher","first-page":"e1004390","DOI":"10.1371\/journal.pmed.1004390","volume":"21","author":"P Logullo","year":"2024","unstructured":"Logullo P, van Zuuren EJ, Winchester CC, et al. ACcurate COnsensus Reporting Document (ACCORD) explanation and elaboration: guidance and examples to support reporting consensus methods. PLoS Med. 2024;21(5):e1004390.","journal-title":"PLoS Med"},{"key":"9078_CR32","doi-asserted-by":"publisher","first-page":"1535869","DOI":"10.3389\/fonc.2024.1535869","volume":"14","author":"PJ Ho","year":"2025","unstructured":"Ho PJ, Quach H, Sidiqi MH, et al. Management of CAR-T cell therapy in patients with multiple myeloma: a systematic review and expert consensus in Australia. Front Oncol. 2025;14:1535869.","journal-title":"Front Oncol"},{"key":"9078_CR33","doi-asserted-by":"publisher","first-page":"103582","DOI":"10.1016\/j.eclinm.2025.103582","volume":"89","author":"V Solitano","year":"2025","unstructured":"Solitano V, Han\u017eel J, Ma C, et al. An international consensus on the design of clinical trials for advanced combination treatment (ACT) in inflammatory bowel disease. EClinicalMedicine. 2025;89:103582.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"9078_CR34","doi-asserted-by":"publisher","first-page":"yoaf011","DOI":"10.1093\/jscdis\/yoaf011","volume":"2","author":"J Kanter","year":"2025","unstructured":"Kanter J, Frei-Jones M, Manwani D, et al. The development of consensus recommendation to improve practice harmonization for sickle cell disease through the National Alliance of Sickle Cell Centers. J Sick Cell Dis. 2025;2(1):yoaf011.","journal-title":"J Sick Cell Dis"},{"issue":"1","key":"9078_CR35","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1017\/S0266462300002774","volume":"2","author":"RH Brook","year":"1986","unstructured":"Brook RH, Chassin MR, Fink A, Solomon DH, Kosecoff J, Park RE. A method for the detailed assessment of the appropriateness of medical technologies. Int J Technol Assess Health Care. 1986;2(1):53\u201363.","journal-title":"Int J Technol Assess Health Care"},{"issue":"11","key":"9078_CR36","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1080\/03007995.2020.1816946","volume":"36","author":"R Jandhyala","year":"2020","unstructured":"Jandhyala R. Delphi, non-RAND modified Delphi, RAND\/UCLA appropriateness method and a novel group awareness and consensus methodology for consensus measurement: a systematic literature review. Curr Med Res Opin. 2020;36(11):1873\u201387.","journal-title":"Curr Med Res Opin"},{"key":"9078_CR37","unstructured":"Scottish Pharmacy Services. Pharmacy Oversight and Supervision Requirements for Preparation of Licensed ATMPs. 2020. Available at: https:\/\/www.sps.nhs.uk\/articles\/pharmacy-oversight-and-supervision-requirements-for-preparation-of-licensed-atmps\/. Accessed 24 Aug 2025."},{"key":"9078_CR38","unstructured":"International Pharmaceutical Federation, Hospital Pharmacy Section. Revised FIP Basel statements on the future of hospital pharmacy. The Hague (Netherlands): International Pharmaceutical Federation. 2015. Available at: https:\/\/www.fip.org\/files\/fip\/FIP_BASEL_STATEMENTS_ON_THE_FUTURE_OF_HOSPITAL_PHARMACY_2015.pdf. Accessed 24 Aug 2025."},{"key":"9078_CR39","unstructured":"Fitch K, Bernstein SJ, Aguilar MD, RAND Corporation. The RAND\/UCLA appropriateness method user\u2019s manual. Santa Monica, CA:. 2001. Available at: https:\/\/www.rand.org\/pubs\/monograph_reports\/MR1269.html. Accessed 24 Aug 2025."},{"issue":"2","key":"9078_CR40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/anae.15808","volume":"78","author":"LC Savic","year":"2023","unstructured":"Savic LC, Smith AF. How to conduct a Delphi consensus process. Anaesthesia. 2023;78(2):247\u201350.","journal-title":"Anaesthesia"},{"issue":"12","key":"9078_CR41","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/S0895-4356(03)00211-7","volume":"56","author":"B Graham","year":"2003","unstructured":"Graham B, Regehr G, Wright JG. Delphi as a method to establish consensus for diagnostic criteria. J Clin Epidemiol. 2003;56(12):1150\u20136.","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"9078_CR42","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1108\/FS-11-2018-0095","volume":"21","author":"JW Zartha Sossa","year":"2019","unstructured":"Zartha Sossa JW, Halal W, Hernandez Zarta R. Delphi method: analysis of rounds, stakeholder and statistical indicators. Foresight. 2019;21(5):525\u201344.","journal-title":"Foresight"},{"issue":"2","key":"9078_CR43","first-page":"257","volume":"14","author":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences","year":"2023","unstructured":"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences. & peking union medical college, China medical board, Chinese hospital association pharmaceutical specialized committee. Expert consensus on the core competency framework of Chinese clinical pharmacist. Med J Peking Union Med Coll Hosp. 2023;14(2):257\u201365.","journal-title":"Med J Peking Union Med Coll Hosp"},{"issue":"8","key":"9078_CR44","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1080\/14712598.2018.1495192","volume":"18","author":"N Stoner","year":"2018","unstructured":"Stoner N. Are UK hospital pharmacy departments ready for the rise of gene therapy medicinal products? Expert Opin Biol Ther. 2018;18(8):837\u201340.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"9078_CR45","first-page":"03","volume":"51","author":"TL Webb","year":"2021","unstructured":"Webb TL, Hong E. GMO medicines and hospital pharmacy practice: a review. J Phar Pract Res. 2021;51(3):03\u2013210.","journal-title":"J Phar Pract Res"},{"key":"9078_CR46","first-page":"5","volume":"4","author":"PS Sharif","year":"2011","unstructured":"Sharif PS, Javadi M, Asghari F. Pharmacy ethics: evaluation pharmacists\u2019 ethical attitude. J Med Ethics Hist Med. 2011;4:5.","journal-title":"J Med Ethics Hist Med"},{"key":"9078_CR47","doi-asserted-by":"publisher","first-page":"1397531","DOI":"10.3389\/fphar.2024.1397531","volume":"15","author":"T Desmet","year":"2025","unstructured":"Desmet T, Michelsen S, Van den Brande E, Van Dyck W, Simoens S, Huys I. Towards implementing new payment models for the reimbursement of high-cost, curative therapies in Europe: insights from semi-structured interviews. Front Pharmacol. 2025;15:1397531.","journal-title":"Front Pharmacol"},{"issue":"3","key":"9078_CR48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.healthpol.2017.11.012","volume":"122","author":"E Hanna","year":"2018","unstructured":"Hanna E, Toumi M, Dussart C, et al. Funding breakthrough therapies: a systematic review and recommendation. Health Policy. 2018;122(3):217\u201329.","journal-title":"Health Policy"},{"issue":"2","key":"9078_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10198-021-01276-2","volume":"23","author":"E Gon\u00e7alves","year":"2022","unstructured":"Gon\u00e7alves E. Value-based pricing for advanced therapy medicinal products: emerging affordability solutions. Eur J Health Econ. 2022;23(2):155\u201363.","journal-title":"Eur J Health Econ"},{"issue":"4","key":"9078_CR50","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s40258-025-00960-1","volume":"23","author":"F McElwee","year":"2025","unstructured":"McElwee F, Cole A, Kaliappan G, Masters A, Steuten L. Alternative payment models for innovative medicines: a framework for effective implementation. Appl Health Econ Health Policy. 2025;23(4):535\u201349.","journal-title":"Appl Health Econ Health Policy"},{"issue":"2","key":"9078_CR51","first-page":"88","volume":"46","author":"JL Poveda-Andr\u00e9s","year":"2022","unstructured":"Poveda-Andr\u00e9s JL, Ruiz-Caldes MJ, Carreras-Soler MJ, et al. Pharmacotherapeutic management of advanced therapy medicinal products. Farm Hosp. 2022;46(2):88\u201395.","journal-title":"Farm Hosp"},{"key":"9078_CR52","doi-asserted-by":"publisher","unstructured":"Rioufol C, Wichmann C. Receiving, handling, storage, thawing, distribution, and administration of CAR-T Cells shipped from the manufacturing facility. In: Kr\u00f6ger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, eds. The EBMT\/EHA CAR-T Cell Handbook. Cham: Springer. 2022;37\u201343. https:\/\/doi.org\/10.1007\/978-3-030-94353-0_7.","DOI":"10.1007\/978-3-030-94353-0_7"},{"key":"9078_CR53","doi-asserted-by":"publisher","first-page":"1591751","DOI":"10.3389\/fmed.2025.1591751","volume":"12","author":"H von der Leyen","year":"2025","unstructured":"von der Leyen H, Delgado J, Mazouz C, Schmitt M, Caplan V. Implementation of a quality management system for decentralized manufacturing of cell and gene therapy products - technical and regulatory considerations. Front Med (Lausanne). 2025;12:1591751.","journal-title":"Front Med (Lausanne)"},{"issue":"10","key":"9078_CR54","doi-asserted-by":"publisher","first-page":"719","DOI":"10.2217\/rme-2022-0064","volume":"17","author":"E Bicudo","year":"2022","unstructured":"Bicudo E, Brass I. Institutional and infrastructure challenges for hospitals producing advanced therapies in the UK: the concept of \u2018point-of-care manufacturing readiness\u2019. Regen Med. 2022;17(10):719\u201337.","journal-title":"Regen Med"},{"issue":"8","key":"9078_CR55","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.jcyt.2025.04.065","volume":"27","author":"B Pourroy","year":"2025","unstructured":"Pourroy B, Madelaine I, Carvalho M, et al. The pharmaceutical circuit of advanced therapy medicinal products-guidelines of the French society for oncology pharmacy. Cytotherapy. 2025;27(8):1023\u201330.","journal-title":"Cytotherapy"},{"issue":"8","key":"9078_CR56","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1002\/bcp.70104","volume":"91","author":"FJH Henderson","year":"2025","unstructured":"Henderson FJH, Hill SL. The clinical toxicity of advanced therapy medicinal products. Br J Clin Pharmacol. 2025;91(8):2222\u201340.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"9078_CR57","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1136\/ejhpharm-2022-003470","volume":"31","author":"A Lozano-Bl\u00e1zquez","year":"2024","unstructured":"Lozano-Bl\u00e1zquez A, Makridaki D, Plesan CR, et al. Advanced therapy medicinal products. Eur J Hosp Pharm. 2024;31(1):63\u20135.","journal-title":"Eur J Hosp Pharm"},{"issue":"1","key":"9078_CR58","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40545-023-00592-7","volume":"16","author":"N Chamoun","year":"2023","unstructured":"Chamoun N, Ramia E, Sacre H, et al. Validation of the specialized competency framework for pharmacists in hospital settings (SCF\u2013PHS): a cross-sectional study. J Pharm Policy Pract. 2023;16(1):86.","journal-title":"J Pharm Policy Pract"},{"key":"9078_CR59","doi-asserted-by":"publisher","first-page":"1442643","DOI":"10.3389\/fmed.2024.1442643","volume":"11","author":"A Al-Haqan","year":"2024","unstructured":"Al-Haqan A, Waheedi S, Abdullah I, et al. Competency development for pharmacy: adopting and adapting the FIP global advanced development framework. Front Med (Lausanne). 2024;11:1442643.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"9078_CR60","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s40545-023-00602-8","volume":"16","author":"H Sacre","year":"2023","unstructured":"Sacre H, Saab M, Haddad C, et al. The specialized competency framework for industry pharmacists (SCF-IP): validation and pilot assessment. J Pharm Policy Pract. 2023;16(1):96.","journal-title":"J Pharm Policy Pract"},{"issue":"1","key":"9078_CR61","doi-asserted-by":"publisher","first-page":"2470848","DOI":"10.1080\/20523211.2025.2470848","volume":"18","author":"M Barakat","year":"2025","unstructured":"Barakat M, Sallam M. Pharmacy workforce: a systematic review of key drivers of pharmacists\u2019 satisfaction and retention. J Pharm Policy Pract. 2025;18(1):2470848.","journal-title":"J Pharm Policy Pract"},{"issue":"2","key":"9078_CR62","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.sapharm.2022.09.013","volume":"19","author":"J McMullen","year":"2023","unstructured":"McMullen J, Arakawa N, Anderson C, Pattison L, McGrath S. A systematic review of contemporary competency-based education and training for pharmacy practitioners and students. Res Social Adm Pharm. 2023;19(2):192\u2013217.","journal-title":"Res Social Adm Pharm"},{"issue":"11S","key":"9078_CR63","doi-asserted-by":"publisher","first-page":"S164","DOI":"10.1097\/ACM.0000000000004366","volume":"96","author":"HL Anderson","year":"2021","unstructured":"Anderson HL, Kurtz J, West DC. Implementation and use of workplace-based assessment in clinical learning environments: a scoping review. Acad Med. 2021;96(11S):S164\u201374.","journal-title":"Acad Med"},{"key":"9078_CR64","unstructured":"NHS. Advanced therapy medicinal products. Available at: https:\/\/www.england.nhs.uk\/commissioning\/spec-services\/advanced-therapy-medicinal-products\/. Accessed August 24, 2025."},{"issue":"2","key":"9078_CR65","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1109\/TE.2023.3347273","volume":"67","author":"H Vargas","year":"2024","unstructured":"Vargas H, Heradio R, Farias G, et al. A pragmatic framework for assessing learning outcomes in competency-based courses. IEEE Trans Educ. 2024;67(2):224\u201333.","journal-title":"IEEE Trans Educ"},{"issue":"5","key":"9078_CR66","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1177\/0018578718791516","volume":"54","author":"N French","year":"2019","unstructured":"French N, Giuliano C, Dehoorne-Smith M. Evaluation of a hospital pharmacist annual competency program. Hosp Pharm. 2019;54(5):300\u20138.","journal-title":"Hosp Pharm"},{"issue":"1","key":"9078_CR67","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/jac5.1201","volume":"3","author":"JP Engle","year":"2020","unstructured":"Engle JP, Dick TB, Bryant G, et al. Credentialing and privileging for clinical pharmacists. J Am Coll Clin Pharm. 2020;3(1):133\u201344.","journal-title":"J Am Coll Clin Pharm"}],"container-title":["BMC Medical Education"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12909-026-09078-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12909-026-09078-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12909-026-09078-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:04:06Z","timestamp":1777885446000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12909-026-09078-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,25]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9078"],"URL":"https:\/\/doi.org\/10.1186\/s12909-026-09078-x","relation":{},"ISSN":["1472-6920"],"issn-type":[{"value":"1472-6920","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,25]]},"assertion":[{"value":"3 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval number (HE-0132-2024) was obtained from the Sub-Panel on Social Science & Humanities Research Ethics (Human Participants), Research Ethics Panel on Research Committee of the University of Macau. Confidentiality was maintained. Informed consent by email was obtained from the Delphi experts. Published data were handled anonymously and used only for research. This study adhered to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participant"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"715"}}